JP2011516607A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516607A5 JP2011516607A5 JP2011505026A JP2011505026A JP2011516607A5 JP 2011516607 A5 JP2011516607 A5 JP 2011516607A5 JP 2011505026 A JP2011505026 A JP 2011505026A JP 2011505026 A JP2011505026 A JP 2011505026A JP 2011516607 A5 JP2011516607 A5 JP 2011516607A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- antagonist
- heteroaryl
- lfa
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000005557 antagonist Substances 0.000 claims description 46
- 102100022339 Integrin alpha-L Human genes 0.000 claims description 43
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 43
- 125000001072 heteroaryl group Chemical group 0.000 claims description 40
- 125000003118 aryl group Chemical group 0.000 claims description 38
- -1 heteroaliphatic Chemical group 0.000 claims description 32
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 125000002723 alicyclic group Chemical group 0.000 claims description 26
- 125000001931 aliphatic group Chemical group 0.000 claims description 24
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 24
- 150000002431 hydrogen Chemical class 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical group 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 6
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims description 6
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims description 6
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims description 6
- 125000002070 alkenylidene group Chemical group 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- BWOVZCWSJFYBRM-UHFFFAOYSA-N carbononitridic isocyanate Chemical group O=C=NC#N BWOVZCWSJFYBRM-UHFFFAOYSA-N 0.000 claims description 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 6
- 239000003246 corticosteroid Substances 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 239000002955 immunomodulating agent Substances 0.000 claims description 6
- 229940121354 immunomodulator Drugs 0.000 claims description 6
- 230000002584 immunomodulator Effects 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical group S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 6
- KBOPZPXVLCULAV-UHFFFAOYSA-M mesalaminate(1-) Chemical group NC1=CC=C(O)C(C([O-])=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-M 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000003961 penetration enhancing agent Substances 0.000 claims description 4
- 229920005862 polyol Polymers 0.000 claims description 4
- 150000003077 polyols Chemical class 0.000 claims description 4
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
- 108010036949 Cyclosporine Proteins 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 3
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- JTNFLOSMZURXJM-UHFFFAOYSA-N NS(S)(=O)=O Chemical compound NS(S)(=O)=O JTNFLOSMZURXJM-UHFFFAOYSA-N 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 229960002964 adalimumab Drugs 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 3
- 229960002170 azathioprine Drugs 0.000 claims description 3
- 229960004436 budesonide Drugs 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 229960001265 ciclosporin Drugs 0.000 claims description 3
- 229960003405 ciprofloxacin Drugs 0.000 claims description 3
- 230000002860 competitive effect Effects 0.000 claims description 3
- 229930182912 cyclosporin Natural products 0.000 claims description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 3
- 229960000598 infliximab Drugs 0.000 claims description 3
- 229960001428 mercaptopurine Drugs 0.000 claims description 3
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims description 3
- 229960004963 mesalazine Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 3
- 229960000282 metronidazole Drugs 0.000 claims description 3
- 239000011859 microparticle Substances 0.000 claims description 3
- 125000002950 monocyclic group Chemical group 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims description 3
- 229960005330 pimecrolimus Drugs 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 229960004618 prednisone Drugs 0.000 claims description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 3
- 229960002930 sirolimus Drugs 0.000 claims description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 3
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 3
- 229960001940 sulfasalazine Drugs 0.000 claims description 3
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 229960001967 tacrolimus Drugs 0.000 claims description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 3
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 239000012062 aqueous buffer Substances 0.000 claims description 2
- 239000002585 base Substances 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 239000008139 complexing agent Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000003979 granulating agent Substances 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229910003002 lithium salt Inorganic materials 0.000 claims description 2
- 159000000002 lithium salts Chemical class 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 229960002969 oleic acid Drugs 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- 159000000000 sodium salts Chemical group 0.000 claims description 2
- 229940083466 soybean lecithin Drugs 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 150000003462 sulfoxides Chemical group 0.000 claims description 2
- 150000003505 terpenes Chemical class 0.000 claims description 2
- 235000007586 terpenes Nutrition 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 238000009736 wetting Methods 0.000 claims description 2
- 150000003751 zinc Chemical class 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- 235000005985 organic acids Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 description 27
- 238000009472 formulation Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 0 CIN(C1*)C(*)(*)Cc2c1cc(*)c(C(NC(*)(*)*)=O)c2* Chemical compound CIN(C1*)C(*)(*)Cc2c1cc(*)c(C(NC(*)(*)*)=O)c2* 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 206010030983 oral lichen planus Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4516508P | 2008-04-15 | 2008-04-15 | |
| US61/045,165 | 2008-04-15 | ||
| PCT/US2009/002385 WO2009128932A1 (en) | 2008-04-15 | 2009-04-15 | Delivery of lfa-1 antagonists to the gastrointestinal system |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014080740A Division JP2014133751A (ja) | 2008-04-15 | 2014-04-10 | 胃腸系へのｌｆａ−１アンタゴニストの送達 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011516607A JP2011516607A (ja) | 2011-05-26 |
| JP2011516607A5 true JP2011516607A5 (enExample) | 2012-06-07 |
Family
ID=41164199
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505026A Withdrawn JP2011516607A (ja) | 2008-04-15 | 2009-04-15 | 胃腸系へのｌｆａ−１アンタゴニストの送達 |
| JP2014080740A Withdrawn JP2014133751A (ja) | 2008-04-15 | 2014-04-10 | 胃腸系へのｌｆａ−１アンタゴニストの送達 |
| JP2016105884A Withdrawn JP2016153432A (ja) | 2008-04-15 | 2016-05-27 | 胃腸系へのｌｆａ−１アンタゴニストの送達 |
| JP2018081289A Pending JP2018127485A (ja) | 2008-04-15 | 2018-04-20 | 胃腸系へのｌｆａ−１アンタゴニストの送達 |
| JP2019190144A Pending JP2020023546A (ja) | 2008-04-15 | 2019-10-17 | 胃腸系へのｌｆａ−１アンタゴニストの送達 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014080740A Withdrawn JP2014133751A (ja) | 2008-04-15 | 2014-04-10 | 胃腸系へのｌｆａ−１アンタゴニストの送達 |
| JP2016105884A Withdrawn JP2016153432A (ja) | 2008-04-15 | 2016-05-27 | 胃腸系へのｌｆａ−１アンタゴニストの送達 |
| JP2018081289A Pending JP2018127485A (ja) | 2008-04-15 | 2018-04-20 | 胃腸系へのｌｆａ−１アンタゴニストの送達 |
| JP2019190144A Pending JP2020023546A (ja) | 2008-04-15 | 2019-10-17 | 胃腸系へのｌｆａ−１アンタゴニストの送達 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090258069A1 (enExample) |
| EP (1) | EP2276508A4 (enExample) |
| JP (5) | JP2011516607A (enExample) |
| CN (1) | CN102065893A (enExample) |
| WO (1) | WO2009128932A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2544678C (en) | 2003-11-05 | 2013-12-31 | Sunesis Pharmaceuticals, Inc. | Modulators of cellular adhesion |
| AU2006247136C1 (en) | 2005-05-17 | 2020-01-16 | Bausch + Lomb Ireland Limited | Compositions and methods for treatment of eye disorders |
| MX2010004281A (es) | 2007-10-19 | 2010-09-10 | Sarcode Corp | Composiciones y metodos para el tratamiento de la retinopatia diabetica. |
| US20090257957A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders |
| WO2009128934A1 (en) * | 2008-04-15 | 2009-10-22 | Sarcode Corporation | Topical lfa-1 antagonists for use in localized treatment of immune related disorders |
| SG173167A1 (en) | 2009-01-29 | 2011-08-29 | Forsight Labs Llc | Posterior segment drug delivery |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| HUE054113T2 (hu) | 2010-08-05 | 2021-08-30 | Forsight Vision4 Inc | Injekciós készülék gyógyszerbejuttatáshoz |
| EP2600812B1 (en) | 2010-08-05 | 2021-09-22 | ForSight Vision4, Inc. | Apparatus to treat an eye |
| WO2012019139A1 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
| WO2012068549A2 (en) | 2010-11-19 | 2012-05-24 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| US8404859B2 (en) | 2011-03-16 | 2013-03-26 | Hoffmann-La Roche Inc. | Thiazole and thiophene compounds |
| JP6072778B2 (ja) * | 2011-05-23 | 2017-02-01 | シーイーエム—１０２ ファーマシューティカルズ，インコーポレイテッド | フシジン酸を含む組成物およびそのためのパッケージ |
| WO2013003620A2 (en) | 2011-06-28 | 2013-01-03 | Forsight Vision4, Inc. | Diagnostic methods and apparatus |
| EP2739252A4 (en) | 2011-08-05 | 2015-08-12 | Forsight Vision4 Inc | SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE |
| WO2013040247A2 (en) | 2011-09-16 | 2013-03-21 | Forsight Vision4, Inc. | Fluid exchange apparatus and methods |
| CA2852912A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Intellectual Property Limited | Pazopanib formulation |
| WO2013116061A1 (en) | 2012-02-03 | 2013-08-08 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
| WO2013151518A1 (en) * | 2012-04-04 | 2013-10-10 | Mahmut Bilgic | Capsule formulations comprising ceftibuten |
| US9968603B2 (en) | 2013-03-14 | 2018-05-15 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| EP2978393B1 (en) | 2013-03-28 | 2023-12-27 | ForSight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
| UA119324C2 (uk) * | 2013-04-02 | 2019-06-10 | Теміс Медікер Лімітед | Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні |
| KR101692578B1 (ko) * | 2013-04-18 | 2017-01-03 | 삼진제약주식회사 | 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물 |
| EP3169289B1 (en) | 2014-07-15 | 2020-04-15 | ForSight Vision4, Inc. | Ocular implant delivery device |
| MY182793A (en) | 2014-08-08 | 2021-02-05 | Forsight Vision4 Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| AU2015346450B2 (en) | 2014-11-10 | 2020-01-30 | Forsight Vision4, Inc. | Expandable drug delivery devices and method of use |
| US10561627B2 (en) * | 2014-12-31 | 2020-02-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films |
| US11007161B1 (en) | 2014-12-31 | 2021-05-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films |
| JP6912475B2 (ja) | 2015-11-20 | 2021-08-04 | フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． | 持続放出性薬物送達機器用の多孔質構造体 |
| KR20180133440A (ko) | 2016-04-05 | 2018-12-14 | 포사이트 비젼4, 인크. | 이식 가능한 안구 약물 전달 장치 |
| EP3713528A1 (en) | 2017-11-21 | 2020-09-30 | ForSight Vision4, Inc. | Fluid exchange apparatus for expandable port delivery system and methods of use |
| EP3866793A4 (en) * | 2018-10-15 | 2022-07-27 | Cedars-Sinai Medical Center | METHODS OF TREATMENT AND DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE |
| CN111205275A (zh) * | 2020-04-22 | 2020-05-29 | 南京佰麦生物技术有限公司 | 立他司特晶型及其制备方法 |
| CN112679469B (zh) * | 2020-12-29 | 2021-11-16 | 山东研峰新材料科技有限公司 | 一种四氢异喹啉类衍生物、制备方法及应用 |
| USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
| CN119857104B (zh) * | 2025-01-13 | 2025-12-19 | 山东大学 | 一种定位成形的液体水凝胶及其制备方法与应用 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204261B1 (en) * | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4931279A (en) * | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
| US4668506A (en) * | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| US4713244A (en) * | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| CA1338839C (en) * | 1988-01-29 | 1997-01-14 | Yoshio Sasaki | Controlled release formulation |
| US5424399A (en) * | 1988-06-28 | 1995-06-13 | The Children's Medical Center Corporation | Human CR3α/β heterodimers |
| US5149780A (en) * | 1988-10-03 | 1992-09-22 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
| CH679207A5 (enExample) * | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
| AU8631991A (en) * | 1990-08-27 | 1992-03-17 | Cetus Corporation | Cd18 peptide medicaments for the treatment of disease |
| US5288854A (en) * | 1990-11-28 | 1994-02-22 | Center For Blood Research, Inc. | Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1 |
| CH683149A5 (fr) * | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
| CA2120506C (en) * | 1991-10-04 | 2000-12-12 | Scott M. Whitcup | Treatment of ocular inflammation by blockage of cell adhesion molecules |
| US5298492A (en) * | 1992-08-04 | 1994-03-29 | Schering Corporation | Diamino acid derivatives as antihypertensives |
| ATE161192T1 (de) * | 1992-08-21 | 1998-01-15 | Genentech Inc | Verfahren zur behandlung einer durch lfa-1 vermittelten störung |
| JP3756512B2 (ja) * | 1992-09-21 | 2006-03-15 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 徐放性タンパク質製剤 |
| US5672659A (en) * | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US5397791A (en) * | 1993-08-09 | 1995-03-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| DK0656348T3 (da) * | 1993-12-03 | 2000-09-11 | Hoffmann La Roche | Eddikesyrederivater som medikamenter |
| US5470953A (en) * | 1993-12-23 | 1995-11-28 | Icos Corporation | Human β2 integrin α subunit |
| US5585359A (en) * | 1994-09-29 | 1996-12-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EP0710657B1 (de) * | 1994-11-02 | 1998-08-26 | MERCK PATENT GmbH | Adhäsionsrezeptor-Antagonisten |
| US20020028798A1 (en) * | 1995-12-12 | 2002-03-07 | Omeros Medical Systems | Irrigation solution and method for inhibition of pain and inflammation |
| US5612052A (en) * | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| US5747035A (en) * | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| US5877224A (en) * | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
| US5863910A (en) * | 1996-01-12 | 1999-01-26 | Bolonick; Joel | Treatment of chronic inflammatory disorders of the gastrointestinal tract |
| US5980945A (en) * | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| CA2217134A1 (en) * | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| CA2272565A1 (en) * | 1996-11-27 | 1998-06-04 | Du Pont Pharmaceuticals Company | Integrin receptor antagonists |
| US5968895A (en) * | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US5893985A (en) * | 1997-03-14 | 1999-04-13 | The Lincoln Electric Company | Plasma arc torch |
| JP2002509881A (ja) * | 1998-03-27 | 2002-04-02 | ジェネンテク・インコーポレイテッド | Ｃｄ１１／ｃｄ１８接着レセプター媒介疾患の治療用アンタゴニスト |
| US6331640B1 (en) * | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| IT1304152B1 (it) * | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
| US6670321B1 (en) * | 1998-12-30 | 2003-12-30 | The Children's Medical Center Corporation | Prevention and treatment for retinal ischemia and edema |
| ATE330631T1 (de) * | 1999-01-05 | 2006-07-15 | Univ Southern Australia | Antikörperfragmente zur lokalen behandlung von augenerkrankungen |
| EP1028114A1 (en) * | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
| EP1611881A1 (en) * | 1999-03-31 | 2006-01-04 | Janssen Pharmaceutica N.V. | Pregelatinized starch in a controlled release formulation |
| US6294522B1 (en) * | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
| US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| US7521061B2 (en) * | 1999-12-31 | 2009-04-21 | Rutgers, The State University Of New Jersey | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
| EP1251864A4 (en) * | 1999-12-31 | 2006-02-22 | Univ Rutgers | PHARMACEUTICAL FORMULATION COMPRISING A POLYMERIC MIXTURE AND AN ACTIVE COMPOUND FOR TIME-RELEASED RELEASE |
| US20030064105A1 (en) * | 2000-08-25 | 2003-04-03 | Myung-Jin Kim | Lipophilic-coated microparticle containing a protein drug and formulation comprising same |
| US6515124B2 (en) * | 2000-02-09 | 2003-02-04 | Hoffman-La Roche Inc. | Dehydroamino acids |
| WO2001085677A1 (fr) * | 2000-05-05 | 2001-11-15 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derives d'aminoacides et leur application a titre de medicaments |
| CN1705649A (zh) * | 2000-06-29 | 2005-12-07 | 艾伯特公司 | 芳基苯基杂环基硫醚衍生物及其作为抑制细胞粘附的抗炎和免疫抑制剂的用途 |
| AR030817A1 (es) * | 2000-10-02 | 2003-09-03 | Novartis Ag | Derivados de diazacicloalcanodiona |
| US6653478B2 (en) * | 2000-10-27 | 2003-11-25 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators |
| GB0028367D0 (en) * | 2000-11-21 | 2001-01-03 | Celltech Chiroscience Ltd | Chemical compounds |
| CN1592746A (zh) * | 2000-11-28 | 2005-03-09 | 杰南技术公司 | Lfa－1拮抗剂化合物 |
| ATE348829T1 (de) * | 2001-02-06 | 2007-01-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen |
| WO2002098370A2 (en) * | 2001-03-02 | 2002-12-12 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
| JP2005511477A (ja) * | 2001-03-19 | 2005-04-28 | プラエシス ファーマシューティカルズ インコーポレーテッド | 持続放出のための医薬調合物 |
| US6872382B1 (en) * | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| EP1392306B1 (en) * | 2001-06-06 | 2008-01-16 | Aventis Pharma Limited | Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases |
| US7785578B2 (en) * | 2002-10-11 | 2010-08-31 | Aciont, Inc. | Non-invasive ocular drug delivery |
| CA2544678C (en) * | 2003-11-05 | 2013-12-31 | Sunesis Pharmaceuticals, Inc. | Modulators of cellular adhesion |
| AU2006247136C1 (en) * | 2005-05-17 | 2020-01-16 | Bausch + Lomb Ireland Limited | Compositions and methods for treatment of eye disorders |
| US20060286108A1 (en) * | 2005-06-16 | 2006-12-21 | Bell Katherine A | Topical compositions for the treatment of chronic wounds |
| MX2010004281A (es) * | 2007-10-19 | 2010-09-10 | Sarcode Corp | Composiciones y metodos para el tratamiento de la retinopatia diabetica. |
| WO2009128934A1 (en) * | 2008-04-15 | 2009-10-22 | Sarcode Corporation | Topical lfa-1 antagonists for use in localized treatment of immune related disorders |
| US20090257957A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders |
-
2009
- 2009-04-15 CN CN200980121698XA patent/CN102065893A/zh active Pending
- 2009-04-15 EP EP09732599A patent/EP2276508A4/en not_active Ceased
- 2009-04-15 US US12/386,347 patent/US20090258069A1/en not_active Abandoned
- 2009-04-15 JP JP2011505026A patent/JP2011516607A/ja not_active Withdrawn
- 2009-04-15 WO PCT/US2009/002385 patent/WO2009128932A1/en not_active Ceased
-
2014
- 2014-04-10 JP JP2014080740A patent/JP2014133751A/ja not_active Withdrawn
-
2016
- 2016-05-27 JP JP2016105884A patent/JP2016153432A/ja not_active Withdrawn
-
2018
- 2018-04-20 JP JP2018081289A patent/JP2018127485A/ja active Pending
-
2019
- 2019-10-17 JP JP2019190144A patent/JP2020023546A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011516607A5 (enExample) | ||
| JP2011521896A5 (enExample) | ||
| KR100943309B1 (ko) | 의약 조성물 | |
| US10751353B2 (en) | Compositions and methods for treating an aggregation disease or disorder | |
| US20170095453A1 (en) | Low Dose Pharmaceutical Composition | |
| US10426724B2 (en) | Antihistamine compositions, combinations, and use thereof | |
| US20250241936A1 (en) | Compositions and methods for treating an aggregation disease or disorder | |
| EP2762141A1 (en) | Drug for the treatment of allergic rhinitis comprising pgd2 antagonist and histamine antagonist | |
| JP2008535925A (ja) | 難溶性薬剤の改善された溶解プロファイルを有する医薬組成物 | |
| US20020037899A1 (en) | Compositions containing an inhibitor of dihydrofolate reductase and a folate | |
| CN116209447A (zh) | 治疗炎性肠病的方法 | |
| US7858612B2 (en) | Therapeutic agent for inflammatory bowel diseases | |
| WO2010133907A1 (en) | Hexadentate chelators in inflammatory bowel disease | |
| US20080293772A1 (en) | Salts of picotamide | |
| JPH05262747A (ja) | 潰瘍性大腸炎治療剤 | |
| Vet—QC03BA11 | 1314 Cardiovascular Drugs | |
| IL256841A (en) | Metaxalone formulation | |
| OA19858A (en) | Low dose pharmaceutical composition. | |
| KR20160016845A (ko) | 저-투여량 약학 조성물 |